In preclinical trials, the effect of lacosamide administration on animal models of [[epilepsy]] was tested using the Frings audiogenic seizures (AGS)-susceptible mouse model of seizure activity with an [[Effective dose (pharmacology)|effective dose]] (ED<sub>50</sub>) of 0.63&nbsp;mg/kg, i.p.<ref name="Beyreuther 2007 21–42">{{cite journal|last=Beyreuther|first=BK|author2=Freitag J |author3=Heers C |author4=Krebsfanger N |author5=Scharfenecker U |author6=Stohr T |title=Lacosamide: a review of preclinical properties|journal=CNS Drug Rev|year=2007|volume=13|issue=1|pages=21–42|pmid=17461888|url=http://www.ncbi.nlm.nih.gov/pubmed/?term=17461888|accessdate=2 April 2014 |doi=10.1111/j.1527-3458.2007.00001.x}}</ref>  The effect of lacosamide was also assessed using the MES test to detect inhibition of seizure spread.<ref>{{cite journal|last=Borowicz|first=KK|author2=Gaisor M |author3=Kleinrok Z |author4=Czuczwar SJ |title=Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice|journal=Eur J Pharmacol|year=1997|volume=323|issue=1|pages=45–51|pmid=9105875|url=http://www.ncbi.nlm.nih.gov/pubmed/?term=9105875|accessdate=2 April 2014 |doi=10.1016/s0014-2999(97)00020-4}}</ref><ref>{{cite journal|last=Swinyard|first=EA|author2=Brown WC |author3=Godman LS |title=Comparative assays of antiepileptic drugs in mice and rats|journal=J Pharmacol Exp Ther|year=1952|volume=106|issue=3|pages=319–20|pmid=13000628}}<!--|accessdate=2 April 2014--></ref>  Lacosamide administration was successful in preventing the spread of seizures induced by MES in mice (ED<sub>50</sub> = 4.5&nbsp;mg/kg, i.p.) and rats (ED<sub>50</sub> = 3.9&nbsp;mg/kg, p.o.).<ref name="Beyreuther 2007 21–42"/>  In preclinical trials, administration of lacosamide in combination with other AEDs resulted in synergistic anticonvulsant effects. Lacosamide produced effects in animal models of [[essential tremor]], [[tardive dyskinesia]], [[schizophrenia]], and [[anxiety]].<ref>{{cite news|title=SCHWARZ PHARMA Highlights the Results of 13 Lacosamide Data Presentations at North American Regional Epilepsy Congress in San Diego|url=http://www.prnewswire.com/news-releases/schwarz-pharma-highlights-the-results-of-13-lacosamide-data-presentations-at-north-american-regional-epilepsy-congress-in-san-diego-55922847.htm|accessdate=2 April 2014|newspaper=Schwarz Pharma|date=5 December 2006}}</ref>   Preclinical trials found the S-stereoisomer to be less potent than the R-stereoisomer in the treatment of seizures.<ref>{{cite journal|last=LeTiran|first=A|author2=Stables, JP |author3=Kohn, H |title=Functionalized amino acid anticonvulsants: synthesis and pharmacological evaluation of conformationally restricted analogues.|journal=Bioorganic & Medicinal Chemistry|date=Oct 2001|volume=9|issue=10|pages=2693–708|pmid=11557357|doi=10.1016/s0968-0896(01)00204-8}}</ref>

 
==Side-effects and tolerability==

 
The side-effects most commonly leading to discontinuation were [[dizziness]], [[ataxia]], [[vomiting]], [[diplopia]] (double vision), [[nausea]], [[vertigo]], and [[blurred vision]]. These adverse reactions were observed in at least 10% of patients.<ref name="Vimpat"/>  Less common side-effects include [[forgetfulness]], discouragement, feelings of sadness, and lack of appetite.

 
[[Dizziness]] was the most common treatment-related adverse event. Other CNS effects are [[headache]], [[drowsiness]], blurred vision, involuntary movements, weakness, tiredness, memory problems, [[diplopia]], trembling or shaking of the hands, unsteadiness, [[ataxia]].

 
[[Itching]], [[rash]],<ref>Vimpat Side Effects Center http://www.rxlist.com/vimpat-side-effects-drug-center.html</ref> [[pruritus]]

 
Lacosamide is a powdery, white to light yellow crystalline compound. The chemical name of lacosamide is (''R'')-2-acetamido-''N''-benzyl-3-methoxypropionamide and the systemic name is  ''N2''-Acetyl-''N''-benzyl-''O''-methyl-''D''-serinamide.<ref name="Beyreuther 21–42"/><ref>{{cite web|title=Lacosamide|url=http://www.chemspider.com/Chemical-Structure.189902.html|publisher=ChemSpider|accessdate=2 April 2014}}</ref>  Lacosamide is a functionalized amino acid molecule that has high solubility in water and DMSO, with a solubility of 20.1&nbsp;mg/mL in [[phosphate-buffered saline]] (PBS, pH 7.5, 25&nbsp;°C).<ref name="Beyreuther 21–42"/><ref>{{cite journal|last=Biton|first=V|author2=Rosenfeld, WE |author3=Whitesides, J |author4=Fountain, NB |author5=Vaiciene, N |author6= Rudd, GD |title=Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures.|journal=Epilepsia|date=Mar 2008|volume=49|issue=3|pages=418–24|pmid=17888078 |doi=10.1111/j.1528-1167.2007.01317.x}}</ref>   The molecule has six rotatable bonds and one [[aromatic]] ring. Lacosamide melts at 143-144&nbsp;°C and boils at 536.447&nbsp;°C at a pressure of 760 mmHg.<ref name="Lacosamide"/><ref>{{cite journal|last=Kellinghaus|first=C|title=Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.|journal=Therapeutics and clinical risk management|year=2009|volume=5|pages=757–66|pmid=19816574|pmc=2754090|doi=10.2147/tcrm.s5189}}</ref>
